Celltrion says Phase 1 trial shows COVID-19 antibody drug 'well-tolerated' ...Middle East

Yahoo - News
Celltrion says Phase 1 trial shows COVID-19 antibody drug well-tolerated
Celltrion added that no patients treated with CT-P59 in the study have so far required hospitalization or other antiviral therapy as a result of COVID-19. Last month, the South Korean drugmaker said it received regulatory approval for Phase 3 clinical trials of the experimental COVID-19 treatment. The treatment, the most advanced antibody drug in terms of research in South Korea, is directed against the surface of the coronavirus and designed to block it from locking on to human cells.

Hence then, the article about celltrion says phase 1 trial shows covid 19 antibody drug 39 well tolerated 39 was published today ( ) and is available on Yahoo ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Celltrion says Phase 1 trial shows COVID-19 antibody drug 'well-tolerated' )

Apple Storegoogle play

Last updated :

Also on site :



Latest News